社区参与孟加拉国尼帕病毒疫苗试验的意愿。

IF 3.5
Vaccine Pub Date : 2025-08-30 Epub Date: 2025-08-09 DOI:10.1016/j.vaccine.2025.127578
Nazmun Nahar, Shahana Parveen, Emily S Gurley, Probir Kumar Ghosh, Ishrat Jabeen, Md Rifat Haidar, Farhat Jahan, Mohammad Saeed Munim, Kanij Fatema Chanda, Md Wazed Ali, Zubair Akhtar, Tahmina Shirin, Sayera Banu, Atique Iqbal Chowdhury, Asraful Alam, Brian E Dawes, Joan Fusco, Thomas P Monath, Gray Heppner, Stephen P Luby
{"title":"社区参与孟加拉国尼帕病毒疫苗试验的意愿。","authors":"Nazmun Nahar, Shahana Parveen, Emily S Gurley, Probir Kumar Ghosh, Ishrat Jabeen, Md Rifat Haidar, Farhat Jahan, Mohammad Saeed Munim, Kanij Fatema Chanda, Md Wazed Ali, Zubair Akhtar, Tahmina Shirin, Sayera Banu, Atique Iqbal Chowdhury, Asraful Alam, Brian E Dawes, Joan Fusco, Thomas P Monath, Gray Heppner, Stephen P Luby","doi":"10.1016/j.vaccine.2025.127578","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nipah virus (NiV) is a deadly zoonotic disease with pandemic potential, prioritized by the World Health Organization for research and vaccine development. Since Bangladesh has faced annual NiV outbreaks and repeated spillovers since 2001, it is likely to be the site of a Phase II vaccine trial. This study explored people's knowledge about NiV and their willingness to participate in a NiV vaccine trial in Bangladesh.</p><p><strong>Methods: </strong>We conducted a mixed methods study, collecting qualitative and quantitative data from Mirpur township, Dhaka, and NiV-affected Faridpur District. From December 2021 to November 2022, the team interviewed adult male and female respondents responsible for household treatment and vaccination decisions.</p><p><strong>Results: </strong>The team conducted 66 in-depth interviews and 978 survey interviews. Many in-depth interviewees were aware of NiV and, when asked if they would participate in a NiV vaccine trial, responded with one of three options: willing, unwilling, or would decide later. They were concerned about vaccine safety and side effects when making a decision about participation. In the survey, more respondents from Mirpur township, Dhaka, had heard about a disease transmitted from bats to people (57 %, 272/478 vs. 52 %, 262/500) and were willing to participate in a vaccine trial (45 %, 217/478 vs. 22 %, 111/500) than those from Faridpur. A high number expressed willingness to take an investigational NiV vaccine during an outbreak (Dhaka 75 %, 205/272 vs. Faridpur 81 %, 398/491 Faridpur). We did not find any association between knowledge about NiV and willingness to participate in a NiV vaccine trial.</p><p><strong>Conclusion: </strong>Many respondents expressed willingness to participate in a NiV vaccine trial, especially during an outbreak, suggesting that such a trial may be feasible in Bangladesh. Given concerns about safety and side effects, clear communication on these issues may support informed participation.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"62 ","pages":"127578"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Community willingness to participate in a Nipah vaccine trial in Bangladesh.\",\"authors\":\"Nazmun Nahar, Shahana Parveen, Emily S Gurley, Probir Kumar Ghosh, Ishrat Jabeen, Md Rifat Haidar, Farhat Jahan, Mohammad Saeed Munim, Kanij Fatema Chanda, Md Wazed Ali, Zubair Akhtar, Tahmina Shirin, Sayera Banu, Atique Iqbal Chowdhury, Asraful Alam, Brian E Dawes, Joan Fusco, Thomas P Monath, Gray Heppner, Stephen P Luby\",\"doi\":\"10.1016/j.vaccine.2025.127578\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Nipah virus (NiV) is a deadly zoonotic disease with pandemic potential, prioritized by the World Health Organization for research and vaccine development. Since Bangladesh has faced annual NiV outbreaks and repeated spillovers since 2001, it is likely to be the site of a Phase II vaccine trial. This study explored people's knowledge about NiV and their willingness to participate in a NiV vaccine trial in Bangladesh.</p><p><strong>Methods: </strong>We conducted a mixed methods study, collecting qualitative and quantitative data from Mirpur township, Dhaka, and NiV-affected Faridpur District. From December 2021 to November 2022, the team interviewed adult male and female respondents responsible for household treatment and vaccination decisions.</p><p><strong>Results: </strong>The team conducted 66 in-depth interviews and 978 survey interviews. Many in-depth interviewees were aware of NiV and, when asked if they would participate in a NiV vaccine trial, responded with one of three options: willing, unwilling, or would decide later. They were concerned about vaccine safety and side effects when making a decision about participation. In the survey, more respondents from Mirpur township, Dhaka, had heard about a disease transmitted from bats to people (57 %, 272/478 vs. 52 %, 262/500) and were willing to participate in a vaccine trial (45 %, 217/478 vs. 22 %, 111/500) than those from Faridpur. A high number expressed willingness to take an investigational NiV vaccine during an outbreak (Dhaka 75 %, 205/272 vs. Faridpur 81 %, 398/491 Faridpur). We did not find any association between knowledge about NiV and willingness to participate in a NiV vaccine trial.</p><p><strong>Conclusion: </strong>Many respondents expressed willingness to participate in a NiV vaccine trial, especially during an outbreak, suggesting that such a trial may be feasible in Bangladesh. Given concerns about safety and side effects, clear communication on these issues may support informed participation.</p>\",\"PeriodicalId\":94264,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"62 \",\"pages\":\"127578\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.vaccine.2025.127578\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.vaccine.2025.127578","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

尼帕病毒(NiV)是一种致命的人畜共患疾病,具有大流行的潜力,是世界卫生组织研究和开发疫苗的重点。由于孟加拉国自2001年以来每年都面临NiV暴发和反复溢出,因此它很可能成为II期疫苗试验的地点。本研究探讨了人们对NiV的了解以及他们参与孟加拉国NiV疫苗试验的意愿。方法:我们进行了一项混合方法研究,从米尔布尔镇、达卡和受niv影响的法里德布尔地区收集定性和定量数据。从2021年12月至2022年11月,该小组采访了负责家庭治疗和疫苗接种决策的成年男性和女性受访者。结果:团队共进行深度访谈66次,调查访谈978次。许多深入的受访者都知道新冠病毒,当被问及是否会参加新冠病毒疫苗试验时,他们的回答有三种:愿意、不愿意或稍后再决定。在决定是否参与时,他们担心疫苗的安全性和副作用。在调查中,来自达卡米尔普尔镇的更多受访者听说过一种由蝙蝠传播给人的疾病(57%,272/478对52%,262/500),并且愿意参加疫苗试验(45%,217/478对22%,111/500)。许多人表示愿意在疫情期间接种研究性NiV疫苗(达卡75%,205/272对法里德普尔81%,398/491法里德普尔)。我们没有发现对NiV的了解与参与NiV疫苗试验的意愿之间存在任何关联。结论:许多答复者表示愿意参加NiV疫苗试验,特别是在疫情期间,这表明这种试验在孟加拉国可能是可行的。考虑到安全性和副作用,在这些问题上的明确沟通可能有助于知情参与。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Community willingness to participate in a Nipah vaccine trial in Bangladesh.

Introduction: Nipah virus (NiV) is a deadly zoonotic disease with pandemic potential, prioritized by the World Health Organization for research and vaccine development. Since Bangladesh has faced annual NiV outbreaks and repeated spillovers since 2001, it is likely to be the site of a Phase II vaccine trial. This study explored people's knowledge about NiV and their willingness to participate in a NiV vaccine trial in Bangladesh.

Methods: We conducted a mixed methods study, collecting qualitative and quantitative data from Mirpur township, Dhaka, and NiV-affected Faridpur District. From December 2021 to November 2022, the team interviewed adult male and female respondents responsible for household treatment and vaccination decisions.

Results: The team conducted 66 in-depth interviews and 978 survey interviews. Many in-depth interviewees were aware of NiV and, when asked if they would participate in a NiV vaccine trial, responded with one of three options: willing, unwilling, or would decide later. They were concerned about vaccine safety and side effects when making a decision about participation. In the survey, more respondents from Mirpur township, Dhaka, had heard about a disease transmitted from bats to people (57 %, 272/478 vs. 52 %, 262/500) and were willing to participate in a vaccine trial (45 %, 217/478 vs. 22 %, 111/500) than those from Faridpur. A high number expressed willingness to take an investigational NiV vaccine during an outbreak (Dhaka 75 %, 205/272 vs. Faridpur 81 %, 398/491 Faridpur). We did not find any association between knowledge about NiV and willingness to participate in a NiV vaccine trial.

Conclusion: Many respondents expressed willingness to participate in a NiV vaccine trial, especially during an outbreak, suggesting that such a trial may be feasible in Bangladesh. Given concerns about safety and side effects, clear communication on these issues may support informed participation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信